Minimal residual disease assessment in CLL began two decades ago in studies utilizing poorly specific and insensitive two-color FLC methods, referring to all CD19+CD5+ light-chain restricted cells as CLL. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.